696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

The combination of neutrophil-to-lymphocyte ratio (NLR), IMDC score and bone metastases ini the Meet-URO score has shown to better stratify mRCC pts receiving ≥2nd line nivolumab compared with the IMDC score identifying five distinctive prognostic groups [Ther Adv Med Oncol 2021, available at: http://bit.ly/Meet-URO15_score]. This score is an easy tool for clinical practice at no additional costs and its application on first-line...